In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Alexi TallanNationwide Children's Hospital, Center for Childhood Cancer Research, Columbus, OH, USA. 20892, USA.ORCID 0000-0002-6043-3233 Jack KucinskiNationwide Children's Hospital, Center for Childhood Cancer Research, Columbus, OH, USA. 20892, USA.ORCID 0000-0002-1788-1305 Andrew M VontellNationwide Children's Hospital, Center for Childhood Cancer Research, Columbus, OH, USA. 20892, USA.ORCID 0009-0005-5755-1836 Chamithi KarunanayakeNationwide Children's Hospital, Center for Childhood Cancer Research, Columbus, OH, USA. 20892, USA.ORCID 0000-0002-8502-5615 Rachel A HoffmanNationwide Children's Hospital, Center for Childhood Cancer Research, Columbus, OH, USA. 20892, USA.ORCID 0000-0002-0032-2304 Benjamin D SunkelNationwide Children's Hospital, Center for Childhood Cancer Research, Columbus, OH, USA. 20892, USA.ORCID 0000-0003-1376-9567 Cenny TaslimNationwide Children's Hospital, Center for Childhood Cancer Research, Columbus, OH, USA. 20892, USA.ORCID 0000-0003-3302-9099 Genevieve C KendallNationwide Children's Hospital, Center for Childhood Cancer Research, Columbus, OH, USA. 20892, USA.ORCID 0000-0003-3775-2006 Benjamin Z StantonNationwide Children's Hospital, Center for Childhood Cancer Research, Columbus, OH, USA. 20892, USA.ORCID 0000-0002-2613-2955 Funding
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3MTranscriptional Coordination and Gene Regulation by MED12 in the CardiomyocyteR01HL166520 · NHLBI · OHIO STATE UNIVERSITY · PI KEDRYN K BASKIN · 2023 to 2026
$2.3MUnderstanding Infantile Rhabdomyosarcoma Biology and Therapeutic TargetsR01CA272872 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI Genevieve Claire Kendall · 2022 to 2026
$2.1MTraining Program in Basic and Translational Pediatric Oncology ResearchT32CA269052 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI TIMOTHY P CRIPE · 2022 to 2026
$1.8MHistone Acetylation Dynamics and Epigenome DuplicationR01GM144601 · NIGMS · OHIO STATE UNIVERSITY · PI PARTHUN, MARK R · 2022 to 2025
$1.6MTargeting mutant-MYOD1 driven rhabdomyosarcomaU01CA298763 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI Benjamin Stanton · 2025 to 2026
$853kNCI NIH HHS P30 CA016058NCI NIH HHS R01 CA272872NCI NIH HHS T32 CA269052NCI NIH HHS U01 CA298763NHLBI NIH HHS R01 HL166520NIGMS NIH HHS R01 GM144601
6 · The paper itselfAbstract
Fusion positive rhabdomyosarcoma (FP-RMS) is an aggressive soft-tissue sarcoma that most frequently affects children and adolescents. Treatment options and outcomes for children with this cancer remain poor, non-specific, and broadly toxic despite decades of research. The defining molecular drivers of the more aggressive fusion-positive subtype of the disease arise from chromosomal translocations that fuse PAX3 or PAX7 to FOXO1 to form PAX3::FOXO1 or PAX7::FOXO1, encoding fusion oncoprotein transcription factors. Despite their high degree of similarity,
Indexed as
CancerCancer epigenomicsChildhood cancer etiologyChromatinEpigenetic mechanismsFusion oncoproteinsMolecular geneticsPioneer functionRare disease epigeneticsSarcomaSystems biologyTranscription Factors
Identifiers
PMID41756981
PMCPMC12934573
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390